nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—NPY1R—nerve—hypothyroidism	0.034	0.126	CbGeAlD
Atomoxetine—Menstruation irregular—Levothyroxine—hypothyroidism	0.0205	0.0367	CcSEcCtD
Atomoxetine—Menstruation irregular—Dextrothyroxine—hypothyroidism	0.0205	0.0367	CcSEcCtD
Atomoxetine—HTR2A—cerebellar cortex—hypothyroidism	0.0189	0.0699	CbGeAlD
Atomoxetine—Epigastric discomfort—Liotrix—hypothyroidism	0.0158	0.0284	CcSEcCtD
Atomoxetine—CYP2C19—urine—hypothyroidism	0.0157	0.0581	CbGeAlD
Atomoxetine—Menstruation irregular—Liotrix—hypothyroidism	0.015	0.027	CcSEcCtD
Atomoxetine—SLC6A3—nerve—hypothyroidism	0.0143	0.0528	CbGeAlD
Atomoxetine—NPY1R—adrenal cortex—hypothyroidism	0.0131	0.0482	CbGeAlD
Atomoxetine—SLC6A2—nerve—hypothyroidism	0.0115	0.0426	CbGeAlD
Atomoxetine—NPY1R—gonad—hypothyroidism	0.0108	0.0399	CbGeAlD
Atomoxetine—NPY1R—pituitary gland—hypothyroidism	0.0105	0.039	CbGeAlD
Atomoxetine—Coma—Levothyroxine—hypothyroidism	0.0103	0.0185	CcSEcCtD
Atomoxetine—Coma—Dextrothyroxine—hypothyroidism	0.0103	0.0185	CcSEcCtD
Atomoxetine—HTR2A—urine—hypothyroidism	0.0101	0.0371	CbGeAlD
Atomoxetine—NPY1R—adrenal gland—hypothyroidism	0.00942	0.0348	CbGeAlD
Atomoxetine—NPY1R—blood—hypothyroidism	0.00942	0.0348	CbGeAlD
Atomoxetine—CYP3A4—urine—hypothyroidism	0.00931	0.0344	CbGeAlD
Atomoxetine—Disorientation—Dextrothyroxine—hypothyroidism	0.00919	0.0165	CcSEcCtD
Atomoxetine—Disorientation—Levothyroxine—hypothyroidism	0.00919	0.0165	CcSEcCtD
Atomoxetine—CYP2D6—urine—hypothyroidism	0.00916	0.0338	CbGeAlD
Atomoxetine—NPY1R—thyroid gland—hypothyroidism	0.00909	0.0336	CbGeAlD
Atomoxetine—Affect lability—Levothyroxine—hypothyroidism	0.00809	0.0145	CcSEcCtD
Atomoxetine—Affect lability—Dextrothyroxine—hypothyroidism	0.00809	0.0145	CcSEcCtD
Atomoxetine—Tachycardia—Liothyronine—hypothyroidism	0.00803	0.0144	CcSEcCtD
Atomoxetine—Irritability—Levothyroxine—hypothyroidism	0.00785	0.0141	CcSEcCtD
Atomoxetine—Irritability—Dextrothyroxine—hypothyroidism	0.00785	0.0141	CcSEcCtD
Atomoxetine—NPY1R—testis—hypothyroidism	0.00779	0.0288	CbGeAlD
Atomoxetine—Mood swings—Dextrothyroxine—hypothyroidism	0.00779	0.014	CcSEcCtD
Atomoxetine—Mood swings—Levothyroxine—hypothyroidism	0.00779	0.014	CcSEcCtD
Atomoxetine—Coma—Liotrix—hypothyroidism	0.00761	0.0136	CcSEcCtD
Atomoxetine—NPY1R—liver—hypothyroidism	0.00737	0.0272	CbGeAlD
Atomoxetine—HTR2A—nerve—hypothyroidism	0.00694	0.0256	CbGeAlD
Atomoxetine—Sweating increased—Dextrothyroxine—hypothyroidism	0.00692	0.0124	CcSEcCtD
Atomoxetine—Sweating increased—Levothyroxine—hypothyroidism	0.00692	0.0124	CcSEcCtD
Atomoxetine—Disorientation—Liotrix—hypothyroidism	0.00676	0.0121	CcSEcCtD
Atomoxetine—Body temperature increased—Liothyronine—hypothyroidism	0.0065	0.0117	CcSEcCtD
Atomoxetine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00643	0.0115	CcSEcCtD
Atomoxetine—Weight decreased—Levothyroxine—hypothyroidism	0.00643	0.0115	CcSEcCtD
Atomoxetine—Affect lability—Liotrix—hypothyroidism	0.00595	0.0107	CcSEcCtD
Atomoxetine—Irritability—Liotrix—hypothyroidism	0.00577	0.0103	CcSEcCtD
Atomoxetine—Mood swings—Liotrix—hypothyroidism	0.00573	0.0103	CcSEcCtD
Atomoxetine—Flushing—Dextrothyroxine—hypothyroidism	0.00528	0.00946	CcSEcCtD
Atomoxetine—Flushing—Levothyroxine—hypothyroidism	0.00528	0.00946	CcSEcCtD
Atomoxetine—Sweating increased—Liotrix—hypothyroidism	0.00509	0.00913	CcSEcCtD
Atomoxetine—HTR1B—cardiovascular system—hypothyroidism	0.00505	0.0187	CbGeAlD
Atomoxetine—HTR1D—cardiovascular system—hypothyroidism	0.00489	0.0181	CbGeAlD
Atomoxetine—Tension—Levothyroxine—hypothyroidism	0.00486	0.00871	CcSEcCtD
Atomoxetine—Tension—Dextrothyroxine—hypothyroidism	0.00486	0.00871	CcSEcCtD
Atomoxetine—Nervousness—Levothyroxine—hypothyroidism	0.00481	0.00862	CcSEcCtD
Atomoxetine—Nervousness—Dextrothyroxine—hypothyroidism	0.00481	0.00862	CcSEcCtD
Atomoxetine—Weight decreased—Liotrix—hypothyroidism	0.00473	0.00848	CcSEcCtD
Atomoxetine—Tremor—Levothyroxine—hypothyroidism	0.00464	0.00831	CcSEcCtD
Atomoxetine—Tremor—Dextrothyroxine—hypothyroidism	0.00464	0.00831	CcSEcCtD
Atomoxetine—Agitation—Dextrothyroxine—hypothyroidism	0.00455	0.00816	CcSEcCtD
Atomoxetine—Agitation—Levothyroxine—hypothyroidism	0.00455	0.00816	CcSEcCtD
Atomoxetine—Palpitations—Levothyroxine—hypothyroidism	0.00437	0.00784	CcSEcCtD
Atomoxetine—Palpitations—Dextrothyroxine—hypothyroidism	0.00437	0.00784	CcSEcCtD
Atomoxetine—Convulsion—Levothyroxine—hypothyroidism	0.00429	0.00769	CcSEcCtD
Atomoxetine—Convulsion—Dextrothyroxine—hypothyroidism	0.00429	0.00769	CcSEcCtD
Atomoxetine—Arthralgia—Levothyroxine—hypothyroidism	0.00421	0.00756	CcSEcCtD
Atomoxetine—Arthralgia—Dextrothyroxine—hypothyroidism	0.00421	0.00756	CcSEcCtD
Atomoxetine—Anxiety—Levothyroxine—hypothyroidism	0.0042	0.00753	CcSEcCtD
Atomoxetine—Anxiety—Dextrothyroxine—hypothyroidism	0.0042	0.00753	CcSEcCtD
Atomoxetine—Hypoaesthesia—Liotrix—hypothyroidism	0.00416	0.00746	CcSEcCtD
Atomoxetine—Shock—Levothyroxine—hypothyroidism	0.00397	0.00713	CcSEcCtD
Atomoxetine—Shock—Dextrothyroxine—hypothyroidism	0.00397	0.00713	CcSEcCtD
Atomoxetine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00394	0.00707	CcSEcCtD
Atomoxetine—Tachycardia—Levothyroxine—hypothyroidism	0.00394	0.00707	CcSEcCtD
Atomoxetine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00391	0.007	CcSEcCtD
Atomoxetine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00391	0.007	CcSEcCtD
Atomoxetine—Flushing—Liotrix—hypothyroidism	0.00388	0.00696	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00368	0.0066	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00368	0.0066	CcSEcCtD
Atomoxetine—SLC6A2—gonad—hypothyroidism	0.00367	0.0136	CbGeAlD
Atomoxetine—Insomnia—Levothyroxine—hypothyroidism	0.00365	0.00655	CcSEcCtD
Atomoxetine—Insomnia—Dextrothyroxine—hypothyroidism	0.00365	0.00655	CcSEcCtD
Atomoxetine—SLC6A4—blood—hypothyroidism	0.00363	0.0134	CbGeAlD
Atomoxetine—Flatulence—Liotrix—hypothyroidism	0.00359	0.00643	CcSEcCtD
Atomoxetine—Tension—Liotrix—hypothyroidism	0.00357	0.00641	CcSEcCtD
Atomoxetine—Dysgeusia—Liotrix—hypothyroidism	0.00357	0.00639	CcSEcCtD
Atomoxetine—Nervousness—Liotrix—hypothyroidism	0.00354	0.00634	CcSEcCtD
Atomoxetine—Fatigue—Levothyroxine—hypothyroidism	0.00348	0.00624	CcSEcCtD
Atomoxetine—Fatigue—Dextrothyroxine—hypothyroidism	0.00348	0.00624	CcSEcCtD
Atomoxetine—Vision blurred—Liotrix—hypothyroidism	0.00343	0.00615	CcSEcCtD
Atomoxetine—Tremor—Liotrix—hypothyroidism	0.00341	0.00612	CcSEcCtD
Atomoxetine—Agitation—Liotrix—hypothyroidism	0.00335	0.006	CcSEcCtD
Atomoxetine—Feeling abnormal—Levothyroxine—hypothyroidism	0.00333	0.00597	CcSEcCtD
Atomoxetine—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00333	0.00597	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.0033	0.00592	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.0033	0.00592	CcSEcCtD
Atomoxetine—SLC6A3—testis—hypothyroidism	0.00328	0.0121	CbGeAlD
Atomoxetine—Syncope—Liotrix—hypothyroidism	0.00327	0.00585	CcSEcCtD
Atomoxetine—Palpitations—Liotrix—hypothyroidism	0.00322	0.00577	CcSEcCtD
Atomoxetine—Urticaria—Levothyroxine—hypothyroidism	0.00321	0.00575	CcSEcCtD
Atomoxetine—Urticaria—Dextrothyroxine—hypothyroidism	0.00321	0.00575	CcSEcCtD
Atomoxetine—Loss of consciousness—Liotrix—hypothyroidism	0.0032	0.00574	CcSEcCtD
Atomoxetine—SLC6A2—adrenal gland—hypothyroidism	0.0032	0.0118	CbGeAlD
Atomoxetine—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00319	0.00573	CcSEcCtD
Atomoxetine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00319	0.00573	CcSEcCtD
Atomoxetine—Abdominal pain—Levothyroxine—hypothyroidism	0.00319	0.00573	CcSEcCtD
Atomoxetine—Body temperature increased—Levothyroxine—hypothyroidism	0.00319	0.00573	CcSEcCtD
Atomoxetine—Convulsion—Liotrix—hypothyroidism	0.00315	0.00566	CcSEcCtD
Atomoxetine—Arthralgia—Liotrix—hypothyroidism	0.0031	0.00556	CcSEcCtD
Atomoxetine—Chest pain—Liotrix—hypothyroidism	0.0031	0.00556	CcSEcCtD
Atomoxetine—Anxiety—Liotrix—hypothyroidism	0.00309	0.00554	CcSEcCtD
Atomoxetine—SLC6A3—cerebellum—hypothyroidism	0.00303	0.0112	CbGeAlD
Atomoxetine—CYP2C19—blood—hypothyroidism	0.00301	0.0111	CbGeAlD
Atomoxetine—Infection—Liotrix—hypothyroidism	0.00295	0.00529	CcSEcCtD
Atomoxetine—Shock—Liotrix—hypothyroidism	0.00292	0.00524	CcSEcCtD
Atomoxetine—Tachycardia—Liotrix—hypothyroidism	0.0029	0.0052	CcSEcCtD
Atomoxetine—Asthenia—Dextrothyroxine—hypothyroidism	0.0029	0.0052	CcSEcCtD
Atomoxetine—Asthenia—Levothyroxine—hypothyroidism	0.0029	0.0052	CcSEcCtD
Atomoxetine—Hyperhidrosis—Liotrix—hypothyroidism	0.00287	0.00515	CcSEcCtD
Atomoxetine—Pruritus—Dextrothyroxine—hypothyroidism	0.00286	0.00512	CcSEcCtD
Atomoxetine—Pruritus—Levothyroxine—hypothyroidism	0.00286	0.00512	CcSEcCtD
Atomoxetine—Anorexia—Liotrix—hypothyroidism	0.00283	0.00508	CcSEcCtD
Atomoxetine—Diarrhoea—Levothyroxine—hypothyroidism	0.00276	0.00496	CcSEcCtD
Atomoxetine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00276	0.00496	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00271	0.00485	CcSEcCtD
Atomoxetine—Insomnia—Liotrix—hypothyroidism	0.00269	0.00482	CcSEcCtD
Atomoxetine—Paraesthesia—Liotrix—hypothyroidism	0.00267	0.00478	CcSEcCtD
Atomoxetine—SLC6A2—testis—hypothyroidism	0.00265	0.00977	CbGeAlD
Atomoxetine—Decreased appetite—Liotrix—hypothyroidism	0.00258	0.00463	CcSEcCtD
Atomoxetine—HTR2A—heart—hypothyroidism	0.00258	0.00951	CbGeAlD
Atomoxetine—Vomiting—Dextrothyroxine—hypothyroidism	0.00257	0.0046	CcSEcCtD
Atomoxetine—Vomiting—Levothyroxine—hypothyroidism	0.00257	0.0046	CcSEcCtD
Atomoxetine—Fatigue—Liotrix—hypothyroidism	0.00256	0.00459	CcSEcCtD
Atomoxetine—Rash—Levothyroxine—hypothyroidism	0.00255	0.00457	CcSEcCtD
Atomoxetine—Rash—Dextrothyroxine—hypothyroidism	0.00255	0.00457	CcSEcCtD
Atomoxetine—Dermatitis—Levothyroxine—hypothyroidism	0.00254	0.00456	CcSEcCtD
Atomoxetine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00254	0.00456	CcSEcCtD
Atomoxetine—Constipation—Liotrix—hypothyroidism	0.00254	0.00456	CcSEcCtD
Atomoxetine—Headache—Dextrothyroxine—hypothyroidism	0.00253	0.00454	CcSEcCtD
Atomoxetine—Headache—Levothyroxine—hypothyroidism	0.00253	0.00454	CcSEcCtD
Atomoxetine—Feeling abnormal—Liotrix—hypothyroidism	0.00245	0.00439	CcSEcCtD
Atomoxetine—HTR2A—cardiovascular system—hypothyroidism	0.00243	0.00898	CbGeAlD
Atomoxetine—Gastrointestinal pain—Liotrix—hypothyroidism	0.00243	0.00436	CcSEcCtD
Atomoxetine—Nausea—Levothyroxine—hypothyroidism	0.0024	0.0043	CcSEcCtD
Atomoxetine—Nausea—Dextrothyroxine—hypothyroidism	0.0024	0.0043	CcSEcCtD
Atomoxetine—Urticaria—Liotrix—hypothyroidism	0.00236	0.00423	CcSEcCtD
Atomoxetine—CYP2C19—liver—hypothyroidism	0.00235	0.00869	CbGeAlD
Atomoxetine—Abdominal pain—Liotrix—hypothyroidism	0.00235	0.00421	CcSEcCtD
Atomoxetine—Body temperature increased—Liotrix—hypothyroidism	0.00235	0.00421	CcSEcCtD
Atomoxetine—HTR2A—gonad—hypothyroidism	0.00221	0.00815	CbGeAlD
Atomoxetine—HTR2A—pituitary gland—hypothyroidism	0.00215	0.00795	CbGeAlD
Atomoxetine—Asthenia—Liotrix—hypothyroidism	0.00213	0.00382	CcSEcCtD
Atomoxetine—Pruritus—Liotrix—hypothyroidism	0.0021	0.00377	CcSEcCtD
Atomoxetine—Diarrhoea—Liotrix—hypothyroidism	0.00203	0.00365	CcSEcCtD
Atomoxetine—Dizziness—Liotrix—hypothyroidism	0.00197	0.00352	CcSEcCtD
Atomoxetine—HTR2A—adrenal gland—hypothyroidism	0.00192	0.0071	CbGeAlD
Atomoxetine—HTR2A—blood—hypothyroidism	0.00192	0.0071	CbGeAlD
Atomoxetine—Vomiting—Liotrix—hypothyroidism	0.00189	0.00339	CcSEcCtD
Atomoxetine—Rash—Liotrix—hypothyroidism	0.00187	0.00336	CcSEcCtD
Atomoxetine—Dermatitis—Liotrix—hypothyroidism	0.00187	0.00336	CcSEcCtD
Atomoxetine—Headache—Liotrix—hypothyroidism	0.00186	0.00334	CcSEcCtD
Atomoxetine—CYP3A4—blood—hypothyroidism	0.00178	0.00657	CbGeAlD
Atomoxetine—Nausea—Liotrix—hypothyroidism	0.00177	0.00316	CcSEcCtD
Atomoxetine—CYP2D6—blood—hypothyroidism	0.00175	0.00647	CbGeAlD
Atomoxetine—CYP2D6—female gonad—hypothyroidism	0.00163	0.00603	CbGeAlD
Atomoxetine—HTR2A—testis—hypothyroidism	0.00159	0.00587	CbGeAlD
Atomoxetine—HTR2A—liver—hypothyroidism	0.0015	0.00555	CbGeAlD
Atomoxetine—HTR2A—cerebellum—hypothyroidism	0.00147	0.00542	CbGeAlD
Atomoxetine—CYP2D6—testis—hypothyroidism	0.00145	0.00535	CbGeAlD
Atomoxetine—CYP3A4—liver—hypothyroidism	0.00139	0.00514	CbGeAlD
Atomoxetine—CYP2D6—liver—hypothyroidism	0.00137	0.00506	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—hypothyroidism	0.00134	0.00494	CbGeAlD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.00101	0.00587	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000966	0.00563	CbGpPWpGaD
Atomoxetine—NPY1R—G alpha (i) signalling events—POMC—hypothyroidism	0.000923	0.00538	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—TRH—hypothyroidism	0.000904	0.00528	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.00087	0.00507	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—TRH—hypothyroidism	0.000862	0.00503	CbGpPWpGaD
Atomoxetine—HTR6—G alpha (s) signalling events—AVP—hypothyroidism	0.000854	0.00498	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—AVP—hypothyroidism	0.000841	0.0049	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TRH—hypothyroidism	0.000821	0.00479	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—TSHB—hypothyroidism	0.000806	0.0047	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—TSHR—hypothyroidism	0.000806	0.0047	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000775	0.00452	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000771	0.0045	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.00077	0.00449	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000769	0.00449	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000755	0.00441	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000753	0.00439	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—TRH—hypothyroidism	0.000748	0.00437	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.00074	0.00432	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000734	0.00428	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TSHB—hypothyroidism	0.000732	0.00427	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—TSHR—hypothyroidism	0.000732	0.00427	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000697	0.00407	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000691	0.00403	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000691	0.00403	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000686	0.004	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000686	0.004	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000671	0.00392	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000671	0.00392	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000669	0.00391	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000617	0.0036	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—AVP—hypothyroidism	0.000617	0.0036	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—TRH—hypothyroidism	0.00059	0.00344	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—TRH—hypothyroidism	0.000586	0.00342	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000577	0.00337	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—TRH—hypothyroidism	0.000574	0.00335	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000571	0.00333	CbGpPWpGaD
Atomoxetine—HTR6—G alpha (s) signalling events—POMC—hypothyroidism	0.000568	0.00331	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CLTC—hypothyroidism	0.000561	0.00327	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—POMC—hypothyroidism	0.000559	0.00326	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000548	0.0032	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—TSHB—hypothyroidism	0.000526	0.00307	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—TSHR—hypothyroidism	0.000526	0.00307	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—TSHB—hypothyroidism	0.000522	0.00305	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—TSHR—hypothyroidism	0.000522	0.00305	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000511	0.00298	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—TSHB—hypothyroidism	0.000511	0.00298	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—TSHR—hypothyroidism	0.000511	0.00298	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000509	0.00297	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000509	0.00297	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000496	0.00289	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—VAV3—hypothyroidism	0.000493	0.00288	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000486	0.00283	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TRH—hypothyroidism	0.000485	0.00283	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AVP—hypothyroidism	0.000475	0.00277	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000455	0.00265	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AVP—hypothyroidism	0.000453	0.00264	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—VAV3—hypothyroidism	0.000448	0.00261	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000442	0.00258	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000442	0.00258	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TRH—hypothyroidism	0.000435	0.00254	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TSHB—hypothyroidism	0.000432	0.00252	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TSHR—hypothyroidism	0.000432	0.00252	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000432	0.00252	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AVP—hypothyroidism	0.000431	0.00252	CbGpPWpGaD
Atomoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000418	0.00244	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000407	0.00238	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000405	0.00236	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000404	0.00236	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000396	0.00231	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AVP—hypothyroidism	0.000393	0.00229	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TSHB—hypothyroidism	0.000387	0.00226	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TSHR—hypothyroidism	0.000387	0.00226	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SH2B3—hypothyroidism	0.000385	0.00225	CbGpPWpGaD
Atomoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000385	0.00224	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000382	0.00223	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TRH—hypothyroidism	0.000377	0.0022	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000352	0.00205	CbGpPWpGaD
Atomoxetine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000339	0.00198	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—POMC—hypothyroidism	0.000338	0.00197	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TSHB—hypothyroidism	0.000336	0.00196	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TSHR—hypothyroidism	0.000336	0.00196	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TRH—hypothyroidism	0.000334	0.00195	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TRH—hypothyroidism	0.000331	0.00193	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—POMC—hypothyroidism	0.000331	0.00193	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TRH—hypothyroidism	0.000324	0.00189	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—POMC—hypothyroidism	0.000316	0.00184	CbGpPWpGaD
Atomoxetine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000312	0.00182	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AVP—hypothyroidism	0.00031	0.00181	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AVP—hypothyroidism	0.000308	0.0018	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TRH—hypothyroidism	0.000303	0.00177	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AVP—hypothyroidism	0.000301	0.00176	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TRH—hypothyroidism	0.000301	0.00175	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.0003	0.00175	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TSHB—hypothyroidism	0.000297	0.00173	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TSHR—hypothyroidism	0.000297	0.00173	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TSHB—hypothyroidism	0.000295	0.00172	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TSHR—hypothyroidism	0.000295	0.00172	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TRH—hypothyroidism	0.000294	0.00172	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TSHB—hypothyroidism	0.000289	0.00169	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TSHR—hypothyroidism	0.000289	0.00169	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—POMC—hypothyroidism	0.000287	0.00167	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PRL—hypothyroidism	0.000286	0.00167	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000279	0.00162	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000271	0.00158	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TSHB—hypothyroidism	0.00027	0.00158	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TSHR—hypothyroidism	0.00027	0.00158	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000269	0.00157	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TSHB—hypothyroidism	0.000268	0.00156	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TSHR—hypothyroidism	0.000268	0.00156	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VAV3—hypothyroidism	0.000264	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000263	0.00153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TSHB—hypothyroidism	0.000262	0.00153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TSHR—hypothyroidism	0.000262	0.00153	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.00026	0.00152	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AVP—hypothyroidism	0.000255	0.00149	CbGpPWpGaD
Atomoxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000251	0.00147	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000247	0.00144	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TRH—hypothyroidism	0.000246	0.00143	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AVP—hypothyroidism	0.000228	0.00133	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TRH—hypothyroidism	0.000223	0.0013	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000219	0.00128	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TSHB—hypothyroidism	0.000219	0.00128	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TSHR—hypothyroidism	0.000219	0.00128	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TRH—hypothyroidism	0.000213	0.00124	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—IYD—hypothyroidism	0.000212	0.00124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CLTC—hypothyroidism	0.000207	0.00121	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—POMC—hypothyroidism	0.000206	0.0012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CLTC—hypothyroidism	0.000205	0.0012	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—POMC—hypothyroidism	0.000204	0.00119	CbGpPWpGaD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000204	0.00119	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CLTC—hypothyroidism	0.000201	0.00117	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—POMC—hypothyroidism	0.0002	0.00117	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000199	0.00116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TSHB—hypothyroidism	0.000199	0.00116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TSHR—hypothyroidism	0.000199	0.00116	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AVP—hypothyroidism	0.000198	0.00116	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—IYD—hypothyroidism	0.000195	0.00114	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000194	0.00113	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TRH—hypothyroidism	0.000194	0.00113	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TSHB—hypothyroidism	0.00019	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TSHR—hypothyroidism	0.00019	0.00111	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—VAV3—hypothyroidism	0.000182	0.00106	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ATP5O—hypothyroidism	0.000181	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—VAV3—hypothyroidism	0.00018	0.00105	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—POMC—hypothyroidism	0.00018	0.00105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TRH—hypothyroidism	0.000179	0.00104	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TRH—hypothyroidism	0.000178	0.00104	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—VAV3—hypothyroidism	0.000177	0.00103	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AVP—hypothyroidism	0.000175	0.00102	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AVP—hypothyroidism	0.000174	0.00101	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TRH—hypothyroidism	0.000174	0.00101	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000173	0.00101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TSHR—hypothyroidism	0.000173	0.00101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TSHB—hypothyroidism	0.000173	0.00101	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AVP—hypothyroidism	0.00017	0.000993	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPO—hypothyroidism	0.00017	0.000991	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—POMC—hypothyroidism	0.000169	0.000988	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ATP5O—hypothyroidism	0.000166	0.000969	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—POMC—hypothyroidism	0.000166	0.000966	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—VAV3—hypothyroidism	0.000165	0.000964	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—VAV3—hypothyroidism	0.000164	0.000956	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IGF1—hypothyroidism	0.000163	0.00095	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—VAV3—hypothyroidism	0.00016	0.000936	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSHR—hypothyroidism	0.000159	0.00093	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSHB—hypothyroidism	0.000159	0.00093	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AVP—hypothyroidism	0.000159	0.000928	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSHB—hypothyroidism	0.000158	0.000923	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSHR—hypothyroidism	0.000158	0.000923	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AVP—hypothyroidism	0.000158	0.000921	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000157	0.000918	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPO—hypothyroidism	0.000156	0.000911	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSHR—hypothyroidism	0.000155	0.000904	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSHB—hypothyroidism	0.000155	0.000904	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AVP—hypothyroidism	0.000155	0.000902	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CLTC—hypothyroidism	0.000152	0.00089	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—POMC—hypothyroidism	0.000152	0.000885	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SH2B3—hypothyroidism	0.000142	0.000829	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SH2B3—hypothyroidism	0.000141	0.000823	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SH2B3—hypothyroidism	0.000138	0.000806	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—VAV3—hypothyroidism	0.000134	0.000781	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CLTC—hypothyroidism	0.000132	0.000772	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TRH—hypothyroidism	0.000132	0.000769	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—POMC—hypothyroidism	0.000132	0.000769	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AVP—hypothyroidism	0.000129	0.000753	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IYD—hypothyroidism	0.000128	0.000745	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—VAV3—hypothyroidism	0.000122	0.00071	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSHB—hypothyroidism	0.000117	0.000685	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSHR—hypothyroidism	0.000117	0.000685	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AVP—hypothyroidism	0.000117	0.000684	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—POMC—hypothyroidism	0.000116	0.000679	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—VAV3—hypothyroidism	0.000116	0.000679	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—POMC—hypothyroidism	0.000116	0.000674	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TRH—hypothyroidism	0.000114	0.000668	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—POMC—hypothyroidism	0.000113	0.00066	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AVP—hypothyroidism	0.000112	0.000654	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ATP5O—hypothyroidism	0.000109	0.000634	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—POMC—hypothyroidism	0.000108	0.000632	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—POMC—hypothyroidism	0.000106	0.000617	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—VAV3—hypothyroidism	0.000106	0.000616	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRL—hypothyroidism	0.000105	0.000615	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—POMC—hypothyroidism	0.000105	0.000612	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SH2B3—hypothyroidism	0.000105	0.000611	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRL—hypothyroidism	0.000105	0.000611	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—POMC—hypothyroidism	0.000103	0.000599	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRL—hypothyroidism	0.000102	0.000598	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPO—hypothyroidism	0.000102	0.000596	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSHR—hypothyroidism	0.000102	0.000595	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSHB—hypothyroidism	0.000102	0.000595	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AVP—hypothyroidism	0.000102	0.000594	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VAV3—hypothyroidism	9.76e-05	0.000569	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VAV3—hypothyroidism	9.68e-05	0.000565	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VAV3—hypothyroidism	9.48e-05	0.000553	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AVP—hypothyroidism	9.4e-05	0.000548	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AVP—hypothyroidism	9.33e-05	0.000544	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AVP—hypothyroidism	9.13e-05	0.000533	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SH2B3—hypothyroidism	9.09e-05	0.00053	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—hypothyroidism	8.58e-05	0.0005	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TSHB—hypothyroidism	7.86e-05	0.000459	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—hypothyroidism	7.79e-05	0.000454	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRL—hypothyroidism	7.77e-05	0.000453	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—hypothyroidism	7.45e-05	0.000434	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TSHB—hypothyroidism	7.23e-05	0.000422	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VAV3—hypothyroidism	7.18e-05	0.000419	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	7.01e-05	0.000409	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AVP—hypothyroidism	6.92e-05	0.000404	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	6.91e-05	0.000403	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—hypothyroidism	6.76e-05	0.000395	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRL—hypothyroidism	6.74e-05	0.000393	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	6.45e-05	0.000376	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—hypothyroidism	6.25e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VAV3—hypothyroidism	6.24e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—hypothyroidism	6.2e-05	0.000362	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—hypothyroidism	6.07e-05	0.000354	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AVP—hypothyroidism	6.01e-05	0.000351	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—hypothyroidism	6.01e-05	0.000351	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—hypothyroidism	5.96e-05	0.000348	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A5—hypothyroidism	5.89e-05	0.000343	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—hypothyroidism	5.84e-05	0.000341	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	5.41e-05	0.000316	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TSHB—hypothyroidism	4.73e-05	0.000276	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—hypothyroidism	4.6e-05	0.000268	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—hypothyroidism	4.42e-05	0.000258	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	4.21e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—hypothyroidism	3.99e-05	0.000233	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—hypothyroidism	3.84e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A5—hypothyroidism	3.54e-05	0.000206	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—hypothyroidism	3.08e-05	0.00018	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—hypothyroidism	2.83e-05	0.000165	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—hypothyroidism	1.85e-05	0.000108	CbGpPWpGaD
